Drugs / pp65 RNA-LPs
pp65 RNA-LPs
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06389591 | Dec 2024 → Dec 2026 expected | glioblastoma | University of Florida | Recruiting | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | pp65 RNA-LPs | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06389591 ↗ |
| Known as | DP1 | “pp65 RNA loaded lipid particles, pp65 RNA-LPs (Drug Product 1 or DP1)” NCT06389591 ↗ |
| Known as | Drug Product 1 | “pp65 RNA loaded lipid particles, pp65 RNA-LPs (Drug Product 1 or DP1)” NCT06389591 ↗ |
| Known as | pp65 RNA loaded lipid particles | “pp65 RNA loaded lipid particles, pp65 RNA-LPs (Drug Product 1 or DP1)” NCT06389591 ↗ |
| Modality | Messenger RNA (mRNA) | “The first, pp65 RNA-LP, is a messenger RNA (mRNA) pp65 vaccine” NCT06389591 ↗ |
| Route | Intravenous | “administered intravenously” NCT06389591 ↗ |